Emcure Pharmaceuticals share price
NSE: EMCUREBSE: 544210Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,782.60.
- Next results date: the board meets on 3 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹33,586 Cr266th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 6 Aug 2026
- 33.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 5 May 2026
- 6.8
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.20%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 6 Aug 2026
- 21.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 6 Aug 2026
- 25.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 5 May 2026
- 0.24
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,41,41252.9% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 6 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹2,580 Crup 4.48%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹292 Crup 20.00%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 11.3%
Revenue by year
Net profit by year, a loss in red
| ₹ crore | Sep 2024Filed 8 Nov | Dec 2024Filed 6 Feb | Mar 2025Filed 12 Jun | Jun 2025Filed 7 Aug | Sep 2025Filed 11 Nov | Dec 2025Filed 4 Feb | Mar 2026Filed 5 May | Jun 2026Filed 6 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,002 | 1,963 | 2,116 | 2,101 | 2,270 | 2,363 | 2,470 | 2,580 |
| Net profit | 202 | 156 | 197 | 215 | 251 | 231 | 244 | 292 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 10.1% | 8.0% | 9.3% | 10.2% | 11.1% | 9.8% | 9.9% | 11.3% |
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history.PE ratio and valuation history
At or below today's level on 18% of 247 trading days over the last year.
At or below today's level on 65% of 247 trading days over the last year.
At or below today's level on 42% of 247 trading days over the last year.
At or below today's level on 79% of 553 trading days since Jul 2024.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +49.0% | +33.9% | +11.1% | 0.2% |
Mutual funds holding it
74 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 44 of the 51 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 1 more fund filed its first portfolio on record, holding it.Mutual fund holdings
- AddedAdded. Funds that held more shares than at the end of the month before.
- 46
- CutCut. Funds that held fewer shares than at the end of the month before.
- 5
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 22
| Fund | |||
|---|---|---|---|
 Kotak Mid Cap FundKotak Mahindra Mutual Fund | 43,15,000 | 1.26% | ₹838.4 Cr |
 Nippon India Multi Cap FundNippon India Mutual Fund | 15,47,263 | 0.56% | ₹300.6 Cr |
 Aditya Birla Sun Life ELSS Tax Saver FundAditya Birla Sun Life Mutual Fund | 13,49,941 | 1.93% | ₹262.3 Cr |
 SBI Flexicap FundSBI Mutual Fund | 11,28,993 | 0.99% | ₹219.4 Cr |
 HSBC Small Cap FundHSBC Mutual Fund | 8,84,772 | 0.93% | ₹171.9 Cr |
 Axis Small Cap FundAxis Mutual Fund | 8,72,885 | 0.55% | ₹169.6 Cr |
| Nippon India Pharma FundNippon India Mutual Fund | 6,40,910 | 1.36% | ₹124.5 Cr |
| Aditya Birla Sun Life Multi-Cap FundAditya Birla Sun Life Mutual Fund | 4,39,742 | 1.18% | ₹85.4 Cr |
| Aditya Birla Sun Life Small Cap FundAditya Birla Sun Life Mutual Fund | 3,93,680 | 1.25% | ₹76.5 Cr |
| Aditya Birla Sun Life Large & Mid Cap FundAditya Birla Sun Life Mutual Fund | 2,75,555 | 0.96% | ₹53.5 Cr |
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Emcure Pharmaceuticals in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 IPCA LaboratoriesIPCALAB | 49,556 | 37.8 | 6.1 | 22.3 | +10.6% | +68.2% | 17.4% | 17.6% | 0.31% |
 Gland PharmaGLAND | 46,645 | 41.3 | 4.5 | 24.9 | +17.6% | +46.5% | 11.6% | 12.4% | 0.71% |
 Ajanta PharmaAJANTPHARM | 41,035 | 36.2 | 9.1 | 28.0 | +20.2% | +22.0% | 27.3% | 27.2% | 1.83% |
 GlaxoSmithKline PharmaceuticalsGLAXO | 40,737 | 38.1 | 18.0 | 29.1 | +5.8% | +12.4% | 50.6% | 56.3% | 2.37% |
 Sai Life SciencesSAILIFE | 29,639 | 81.9 | 11.9 | 45.0 | – | – | 15.7% | 18.7% | 0.00% |
 WockhardtWOCKPHARMA | 29,276 | 71.6 | 5.9 | 40.4 | +18.4% | – | 8.8% | 7.4% | 0.00% |
 Acutaas ChemicalsACUTAAS | 25,689 | 66.5 | 15.5 | 47.0 | +40.9% | +104.3% | 26.1% | 29.1% | 0.08% |
 Piramal PharmaPPLPHARMA | 25,438 | – | 3.1 | 29.4 | +0.8% | −419.8% | −3.9% | 1.1% | 0.00% |
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.| Ex-date | Type | Per share |
|---|---|---|
| 4 Sep 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹3.60 |
| 14 Aug 2025 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹3.00 |
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
14 Oct · Analysts
Sep 2026
23 Sep · General Updates
Emcure Pharmaceuticals share price by year
Each calendar year to 2025.Emcure Pharmaceuticals share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,364.50 | −5.7% | 1,504.50 | 905.60 |
| 2024 | 1,447.10 | – | 1,526.60 | 1,236.70 |
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 1,776.00 | 1,799.00 | 1,724.80 | 1,770.40 | 1,748.89 | 1,41,412 | 52.9% |
| 22 Oct 2026 | 1,746.00 | 1,811.10 | 1,716.00 | 1,782.60 | 1,770.87 | 1,13,203 | 53.4% |
| 21 Oct 2026 | 1,770.00 | 1,778.90 | 1,725.10 | 1,755.10 | 1,748.55 | 94,219 | 60.7% |
| 19 Oct 2026 | 1,801.00 | 1,829.00 | 1,746.50 | 1,766.60 | 1,789.51 | 1,08,214 | 54.5% |
| 16 Oct 2026 | 1,836.00 | 1,849.30 | 1,816.20 | 1,820.60 | 1,826.45 | 39,565 | 53.5% |
| 15 Oct 2026 | 1,860.00 | 1,885.00 | 1,832.00 | 1,836.00 | 1,840.60 | 66,977 | 66.1% |
| 14 Oct 2026 | 1,855.10 | 1,887.90 | 1,831.40 | 1,866.20 | 1,865.83 | 1,57,573 | 77.4% |
| 13 Oct 2026 | 1,868.00 | 1,878.10 | 1,850.00 | 1,868.60 | 1,861.11 | 55,653 | 45.2% |
| 12 Oct 2026 | 1,828.10 | 1,896.50 | 1,826.10 | 1,867.40 | 1,869.92 | 70,731 | 50.6% |
| 9 Oct 2026 | 1,864.70 | 1,899.00 | 1,816.10 | 1,833.50 | 1,838.77 | 59,497 | 47.1% |
About Emcure Pharmaceuticals
Emcure Pharmaceuticals Limited is a pharmaceutical company headquartered in Pune, Maharashtra. It develops, registers and manufactures medicines. Its capabilities cover oral products, injectables, active pharmaceutical ingredients and peptides, as well as biologics such as Tenecteplase. It was incorporated in 1981 and has 11,686 employees.
The company runs 13 manufacturing facilities across India and five research and development facilities. Its presence spans over 80 countries.
The business is organised into a domestic business in India and an international business. In India, women's health and cardio-metabolic medicines are central to the business, and the company has a Super Specialty Division covering renal, oncology and CNS therapies. It has also entered dermatology and consumer health. The international business has three parts: Europe, Canada and Rest of World. In Europe it has a direct presence in markets such as the UK and Italy. In Canada it is among the top 10 generic pharmaceutical players. The Rest of World business is structured across two segments, antiretroviral (ARV) and non-ARV products.
Emcure was listed on NSE and BSE on 10 July 2024. It entered Canada through the Marcan acquisition, and its US business was demerged. It has since acquired the Manx Healthcare portfolio in Europe. Zuventus Healthcare Limited is now its wholly owned subsidiary after the buyout of the minority stake. In India, it also distributes brands under agreements with Sanofi and Roche, and has an exclusive partnership with Novo Nordisk for semaglutide.
- Legal name
- Emcure Pharmaceuticals Limited
- NSE symbol
- EMCURE
- BSE code
- 544210
- ISIN
- INE168P01015
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Jul 2024
- Face value
- ₹10
- CIN
- L24231PN1981PLC024251
- Corporate identity number, the registrar of companies' code for it